Literature DB >> 1517658

Effect of SMS 201-995 on exocrine pancreatic secretion in a patient with external pancreatic fistula.

T Ohta1, T Nagakawa, K Mori, M Kanno, M Kayahara, K Ueno, I Miyazaki.   

Abstract

The effect of SMS 201-995 on pancreatic exocrine function was studied. The SMS 201-995 was administered to a patient with an artificial external pancreatic fistula following pancreaticoduodenectomy. Variations in pancreatic exocrine function were assessed by determining the volume and components of the fistula fluid during the following periods: 5 d prior to SMS 201-995 administration, for 5 d during actual administration, and for 5 d after it had been discontinued. The SMS 201-995 was administered by subcutaneous injection of 100 micrograms every 12 h for the first 2 d and then 100 micrograms every 6 h for 3 d. This experiment demonstrated that SMS 201-995 has a strong inhibitory effect on pancreatic exocrine function, markedly reducing the amount of fistula fluid and the production of amylase, total protein, and bicarbonate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517658     DOI: 10.1007/bf02924184

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  17 in total

1.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

2.  Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.

Authors:  J Bosch; D Kravetz; J Rodes
Journal:  Gastroenterology       Date:  1981-03       Impact factor: 22.682

3.  Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.

Authors:  S M Wood; M E Kraenzlin; T E Adrian; S R Bloom
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

4.  The hormones of the hypothalamus.

Authors:  R Guillemin; R Burgus
Journal:  Sci Am       Date:  1972-11       Impact factor: 2.142

5.  Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201-995.

Authors:  P Nubiola; J M Badia; F Martinez-Rodenas; M J Gil; M Segura; J Sancho; A Sitges-Serra
Journal:  Ann Surg       Date:  1989-07       Impact factor: 12.969

6.  Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men.

Authors:  B Lembcke; W Creutzfeldt; S Schleser; R Ebert; C Shaw; I Koop
Journal:  Digestion       Date:  1987       Impact factor: 3.216

7.  A comparison of the effects of two somatostatin analogues in a patient with an external pancreatic fistula.

Authors:  H A Heij; H A Bruining; L Verschoor
Journal:  Pancreas       Date:  1986       Impact factor: 3.327

8.  Inhibition by somatostatin of secretin-stimulated pancreatic secretion in man: a study with pure pancreatic juice.

Authors:  S Domschke; W Domschke; W Rösch; S J Konturek; W Sprügel; P Mitznegg; E Wünsch; L Demling
Journal:  Scand J Gastroenterol       Date:  1977       Impact factor: 2.423

9.  Effect of 24-hour somatostatin infusion on glucose homeostasis and on the levels of somatomedin A and pancreatic and thyroid hormones in man.

Authors:  P E Lins; S Efendić; K Hall
Journal:  Acta Med Scand       Date:  1979

Review 10.  The use of somatostatin and its analogs in the treatment of surgical disorders.

Authors:  S Mulvihill; T N Pappas; E Passaro; H T Debas
Journal:  Surgery       Date:  1986-09       Impact factor: 3.982

View more
  3 in total

1.  Subcutaneously administered somatostatin analogue in traumatic pancreatic fistula.

Authors:  A Mahomed
Journal:  Pediatr Surg Int       Date:  1997-02       Impact factor: 1.827

2.  Transpapillary stenting for pancreaticocutaneous fistulas.

Authors:  R A Kozarek; T J Ball; D J Patterson; S L Raltz; L W Traverso; J A Ryan; R C Thirlby
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

3.  A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy.

Authors:  C J Yeo; J L Cameron; M M Maher; P K Sauter; M L Zahurak; M A Talamini; K D Lillemoe; H A Pitt
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.